1Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 1998, 16:2221-2232.
2Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999, 91:763-771.
3Chada S, Mhashilkar A, Roth JA, et al. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel, 2003, 6:169-173.
4Martin B, Bradly GW. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res,1999, 59: 1391-1399.
5Martin LS, Young RS. p53 regulation of DNA excision repair pathways. Mutagenesis, 2002, 17: 149-156.
6Introgen′s Intrabronchial Advexin therapy demonstrates safety and clinical activity in bronchoalveolar lung cancer. Introgen Therapeutics, Inc. News Release, 2003-06-02.
7Phase 2 breast cancer study shows clinical responses in 90 percent of patients treated with Introgen′s Advexin therapy. Introgen Therapeutics, Inc. News Release, 2003-06-02.
8Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002,9:553-566.
9Shimada H, Matsubara H, Ochiai T. p53 gene therapy for esophageal cancer. J Gastroenterol. 2002, 37 Suppl 14:87-91.
10Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest. 2000,118:966-970.
